Prime Medicine (PRME) Announces Proposed IPO

September 23, 2022 4:24 PM EDT

Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.

Prime Medicine (NASDAQ: PRME) has filed for a proposed IPO.

The company describes itself as: "We are a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, Prime Editors, to address the widest spectrum of diseases by deploying our Prime Editing technology, which we believe is a versatile, precise, efficient and broad gene editing technology.
Genetic mutations implicated in disease are diverse and can range from errors of a single base, known as point mutations, to errors that extend beyond a single base, such as insertions, deletions, duplications, or combinations thereof. We believe the ability to alter the human genome at the foundational level may confer the greatest therapeutic impact on human disease.
Gene editing, including platforms such as Prime Editing, is a novel technology that is not yet clinically validated for human therapeutic use. Over the last decade, the field of genetic medicine has evolved tremendously, with groundbreaking advances in gene therapy, cell therapy, RNA therapy, and, more recently, gene editing. These technologies represent dramatic advancements for genetic therapies, but lack the versatility to precisely and efficiently correct the diverse range of mutations or DNA alterations implicated in disease."

J.P. Morgan, Goldman Sachs & Co. LLC, Morgan Stanley, Jefferies will serve as underwriters.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Corporate News, IPOs

Related Entities

JPMorgan, Goldman Sachs, Morgan Stanley, Jefferies & Co, IPO